Alx Oncology Holdings (ALXO) Cash from Investing Activities (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Cash from Investing Activities data on file, last reported at -$105.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 479.95% year-over-year to -$105.0 million; the trailing twelve-month figure through Mar 2026 stood at -$50.1 million (down 157.3% YoY), and the FY2025 full-year result was $82.6 million, down 4.25% from the prior year.
• Cash from Investing Activities eased to -$105.0 million in Q1 2026, from $11.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $42.3 million in Q1 2023 to a low of -$183.9 million in Q1 2022.
• A 5-year average of -$7.5 million and a median of $12.8 million in 2023 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 3540.95% in 2022, while the deepest fall reached 2627342.86% in 2022.
• Tracing ALXO's Cash from Investing Activities over 5 years: stood at $10.9 million in 2022, then tumbled by 252.31% to -$16.7 million in 2023, then surged by 299.11% to $33.2 million in 2024, then sank by 66.15% to $11.2 million in 2025, then tumbled by 1035.07% to -$105.0 million in 2026.
• Business Quant data shows ALXO's Cash from Investing Activities at -$105.0 million in Q1 2026, $11.2 million in Q4 2025, and $21.4 million in Q3 2025.